Translate Bio ^{Priced, Nasdaq: TBIO.X}

We are a leading messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat life-threatening diseases caused by protein or gene dysfunction. Using our proprietary mRNA therapeutic (MRT) platform we create mRNA that encodes functional proteins. We believe that the mRNA design, delivery and manufacturing capabilities of our MRT platform provide us with the most advanced platform for developing product candidates that deliver mRNA encoding functional proteins for therapeutic uses. Our mRNA is delivered to the target cell where the cell's own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. We believe that our MRT platform is broadly applicable across multiple diseases in which the production of a desirable protein can have a therapeutic effect. We are initially focused on restoring the expression of intracellular and transmembrane proteins, areas that have eluded conventional protein therapeutics, in patients with genetic diseases where there is high unmet medical need. We are developing our lead MRT product candidate for the lung, MRT5005, for cystic fibrosis for which we initiated a Phase 1/2 clinical trial in May 2018. We are developing our lead MRT product candidate for the liver, MRT5201, for ornithine transcarbamylase (OTC) deficiency, for which we plan to initiate a Phase 1/2 clinical trial in the first half of 2019.